Bupivacaine/Exparel

Small molecule

Bupivacaine/Exparel is one of 3 small molecule programs targeting Lower Extremity Fracture. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Extremity FractureActive, not recruiting

Lower Extremity FracturePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Lower Extremity Fracture

#DrugCompanyPhaseTrials

Marcaine

Sufenta

1 3

Bupivacaine/Exparel

BBroward Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lower Extremity Fracture1 trial

A Study of Postsurgical Pain Control for Lower Extremity Fractures

Withdrawn·BBroward Health·Phase 1/2·NCT02214810

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bupivacaine/Exparel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupivacaine/Exparel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupivacaine/Exparel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Broward Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBroward Health

Bupivacaine/Exparel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lower Extremity Fracture1 trial

References

Drug Info

Quick Facts

Related News